<DOC>
	<DOCNO>NCT02480153</DOCNO>
	<brief_summary>The study ass efficacy , safety , immunogenicity PF-06410293 adalimumab combination methotrexate subject moderately severly active rheumatoid arthritis inadequate response methotrexate .</brief_summary>
	<brief_title>A Study Of PF-06410293 ( Adalimumab-Pfizer ) And Adalimumab ( Humira ) In Combination With Methotrexate In Subjects With Active Rheumatoid Arthritis ( REFLECTIONS B538-02 ) .</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Diagnosis rheumatoid arthritis base 2010 ACR/EULAR criterion least 4 month . At least 6 tender ( 68 assess ) 6 swollen ( 66 assess ) joint screen baseline . HsCRP equal great 8 mg/L . Must receive methotrexate least 12 week stable dose least 4 week prior first study dose . Evidence untreated inadequately treated latent active TB . Evidence uncontrolled , clinically significant disease , include moderate severe heart failure ( NYHA Class III/IV ) malignancy previous 5 year . History infection require hospitalization parenteral antimicrobial therapy within 6 month prior first dose study drug . May receive 2 dos one biologic therapy ( adalimumab lymphocyte deplete therapy ) . Any second DMARD must wash prior first study dose .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Phase 3</keyword>
	<keyword>adalimumab</keyword>
	<keyword>rheumatoid arthritis</keyword>
</DOC>